CLRB
Cellectar Biosciences Inc

12,708
Loading...
Loading...
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on June 24, 1996 and is headquartered in Florham Park, NJ.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
11

Frequently Asked Questions

What is Market Cap of Cellectar Biosciences Inc?
What is the 52-week high for Cellectar Biosciences Inc?
What is the 52-week low for Cellectar Biosciences Inc?
What is Cellectar Biosciences Inc stock price today?
What was Cellectar Biosciences Inc stock price yesterday?
What is the PE ratio of Cellectar Biosciences Inc?
What is the Price-to-Book ratio of Cellectar Biosciences Inc?
What is the 50-day moving average of Cellectar Biosciences Inc?
How many employess does Cellectar Biosciences Inc has?

Latest CLRB News

View

Advertisement. Remove ads.

Advertisement. Remove ads.